XENOBIOTICS The Metabolism of Reported by Group III, 1-C2.

Slides:



Advertisements
Similar presentations
SITES DRUG BIOTRANSFORMATION
Advertisements

Introduction to Drug Metabolism
Biotransformation Xenobiotic metabolism
ADME METABOLISM. ADME METABOLISM Strictly – the biological breakdown (catabolism) or synthesis (anabolism) of compounds.
Drug/xenobiotic metabolism and pharmacogenetics George Howell III, Ph.D.
PHASE II: Conjugation Reaction R O S E L Y N A. N A R A N J O.
3. Metabolism Many xenobiotics undergo chemical transformation (biotransformation; metabolism) when introduced into biologic systems like the human body.
“What the body does to the drug”
 Most frequently diagnosed cancer worldwide › About 1.35 million new cases diagnosed worldwide each year  Leading cause of cancer deaths in the United.
Phase-II Drug Metabolism
Drug Detoxification Dr. Howaida Supervised by : Prepared by:
Metabolism of Xenobiotics
Drug Metabolism Overview Dr. Arthur Roberts 1. Where to Find Information eLC – most up to date – correct errors 2.
Drug metabolism Prof. M. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General pharmacology.
Biotransformation Xenobiotic metabolism “Essentials of Toxicology” by Klaassen Curtis D. and Watkins John B Chapter 6.
Pharmacokinetics: Bioavailability Asmah Nasser, M.D.
Metabolism - Biotransformation Supplementary readings: Casarett and Doull,Chapter 6 Timbrell, Chapters 4 and 5.
Prepared by Prof .Abdulkader.H.El Daibani
Mechanisms of Toxicity
Chapter 13. Drug Metabolism
NADPH- Cyt. P450 reductase P450 S SOH O 2 H 2 O e NADPH NADP +
Phase II: Conjugation Synthetic reaction of a xenobiotic (or of a Phase I metabolite of a xenobiotic) with an endogenous substance Results in introduction.
Drug Metabolism and Prodrugs
1 Pharmacology Pharmacokinetics –Absorption –Distribution –Biotransformation (metabolism) –Excretion Pharmacodynamics –Receptor binding –Signal transduction.
“Other” detoxication mechanisms P-glycoprotein: ATP-dependent carrier that removes molecules from cells Multidrug resistance associated protein MDR Multispecific.
Phase II: Conjugation Synthetic reaction of a xenobiotic (or of a Phase I metabolite of a xenobiotic) with an endogenous substance Results in introduction.
Terodiline Aromatic p-hydroxylation predominate with R but benzylic hydroxylation is preferred with S (homework)
Section 1, Lecture 4 Phase I reactions-oxidative occur in the endoplasmic reticulum of liver (microsomal fractions) - catalyzed by the microsomal.
Prof. Hanan Hagar Dr.Abdul latif Mahesar Pharmacology Department.
Medical Biochemistry Robert F. Waters, PhD Cytochrome P450 System (Introduction)
CYP Biotransformations
Prof. Hanan Hagar Pharmacology Department By the end of this lecture, students should:  Recognize the importance of biotransformation  Know the different.
Pharmacology Department
Drug Metabolism and Prodrugs
Biotransformation Biotransformation Siva Nageswararao Mekala Assistant Professor Dept. of clinical Pharmacology.
Metabolic Stability Lee, Sang-Hwi. -2- Overview Metabolism is the enzymatic modification of compounds to increase clearance. It is a determinant.
CYP
Detoxification Chemicals entering body (mostly via food) must pass through liver.
Metabolism Chemical transformaion of xenobiotics Occurs in mostly in liver (enzymatic prosesses) Convertion into more hydrophil. subst. - excretion urine.
Pharmacokinetics 2 General Pharmacology M212
Pharmacology I BMS 242 Lecture 4 Pharmacokienetic Principles (3&4): Drug Metabolism and Excretion [Elimination] Dr. Aya M. Serry 2016.
METABOLISME DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA dr. Yunita Sari Pane.
Medicinal Chemistry Lecture Drug Metabolism Lectures 11 & 13 Chemical Delivery Systems Joseph O. Oweta | PHS 2201.
Induction Increased transcription Increased protein synthesis Enhanced stability of protein Synthesis of enzyme with higher catalytic activity Inducible.
Cytochrome P 450 Biochemistry Department. Cytochrome P 450 Unique family of heme proteins present in bacteria, fungi, insects, plants, fish, mammals and.
Farmakodinamik-Metabolisme
METABOLISM / BIOTRANSFORMATION of TOXICANTS.
Oxidation of Aromatic Moieties
Metabolic Changes of Drugs
Chapter 5 Drug Metabolism
Detoxification by the Liver
Metabolism - Biotransformation
Metabolism & Detoxification
METABOLISM / BIOTRANSFORMATION of TOXICANTS.
Metabolism of drugs and xenobiotics
METABOLISM OF XENOBIOTICS
By: Dr. Roshini Murugupillai
Drug Metabolism Drugs are most often eliminated by biotransformation and/or excretion into the urine or bile. The process of metabolism transforms lipophilic.
BIOTRANSFORMATION, Drug metabolism, detoxification
Drug Elimination Drug elimination consists of 2 processes
Induction Increased transcription Increased protein synthesis
Phase-II Drug Metabolism Pharmaceutical Medicinal Chemistry-I
Pharmacokinetics: Metabolism of Drugs
Conceptual Subdivisions of Pharmacology
Conceptual Subdivisions of Pharmacology
Xenobiotic or Drug Metabolism
Pharmacogenetics and Pharmacoepidemiology “PHCY 480”
Drug Detoxification Dr. Howaida Supervised by : Prepared by:
Metabolism of drugs and xenobiotics
BIOAVAILABILITY.
Presentation transcript:

XENOBIOTICS The Metabolism of Reported by Group III, 1-C2

What are Xenobiotics? A compound that is to the body. Xeno = foreign “stranger” may be natural or synthetic may be harmful or safe EXAMPLES OF CARCINOGENIC XENOBIOTICS Food components methyl glyoxal (coffee) Food contaminants aflatoxin B1 Cigarette smoke Industrial (occupational)dibromoethane Industrial (effluent) vinyl chloride Cyanide is one example which is toxic at very low levels

Principal Classes of Xenobiotics Drugs Chemical carcinogens PCB’sInsecticides There are 200,000 of these Most synthetic materials

How does the body handle them? For convenience, the metabolism of xenobiotics is divided into 2 phases There are approximately 30 different enzymes that catalyze xenobiotic compounds 2 phases

1.Phase 1 : : Most common reaction: hydroxylation Some enzymes: monooxygenases microsomal cytochrome-P450s Most common reactions: conjugation methylation Enzymes: transferases 2.Phase 2

Phase 1 Mainly hydroxylation reactions Enzyme: Microsomal Cytochromes P450s Purpose: 1. Make the toxin more water-soluble 2. Sometimes deactivates the toxin

Phase 1: Microsomal cytochrome P450s Large number of isoforms Large number of isoforms All contains heme All contains heme Has a special nomenclature: Has a special nomenclature: CYP FamilySubfamilySpecific # CYPs with >40% similarity CYPs with >55% similarity CYPs with >100% (exact) similarity 2C9

Phase 1: CYP2C9 = A cytochrome that metabolizes warfarin

Phase 1: Microsomal cytochrome P450s Large number of isoforms Large number of isoforms All contains heme All contains heme Has a special nomenclature: Has a special nomenclature: Plenty in liver (in the SER) Plenty in liver (in the SER) Differs from the mitochondrial cytochrome P450 Differs from the mitochondrial cytochrome P450 Has lipid components (primarily lecithin) Has lipid components (primarily lecithin) Inducible (CYP2C9) Inducible (CYP2C9) Some exhibit polymorphism Some exhibit polymorphism Rarely, some contribute to cancer formation Rarely, some contribute to cancer formation

Phase 1: Microsomal cytochrome P450s Large number of isoforms Large number of isoforms All contains heme All contains heme Has a special nomenclature: Has a special nomenclature: Plenty in liver (in the SER) Plenty in liver (in the SER) Differs from the mitochondrial cytochrome P450 Differs from the mitochondrial cytochrome P450 Has lipid components (primarily lecithin) Has lipid components (primarily lecithin) Inducible (CYP2C9) Inducible (CYP2C9) Some exhibit polymorphism Some exhibit polymorphism Rarely, some contribute to cancer formation Rarely, some contribute to cancer formation Inducible (CYP2C9) Inducible (CYP2C9) Some exhibit polymorphism Some exhibit polymorphism Rarely, some contribute to cancer formation Rarely, some contribute to cancer formation Inducible (CYP2C9) Inducible (CYP2C9)

Phase 1: Inducible (CYP2C9) Inducible (CYP2C9) Q: If you give phenobarbital to a patient who is dependent on warfarin, you have to adjust (higher) the dose of the latter or risk bleeding. Why? A: CYP2C9, which metabolizes (inactivates) warfarin is induced by phenobarbital. Q: Drinking along with smoking increases risk of cancer than smoking all by itself. Why? A: CYP2E1, which is induced by ethanol (in liquor) is one of the cytochromes that contribute to the activation of procarcinogens found in tobacco smoke.

Phase 1: Microsomal cytochrome P450s Large number of isoforms Large number of isoforms All contains heme All contains heme Has a special nomenclature: Has a special nomenclature: Plenty in liver (in the SER) Plenty in liver (in the SER) Differs from the mitochondrial cytochrome P450 Differs from the mitochondrial cytochrome P450 Has lipid components (primarily lecithin) Has lipid components (primarily lecithin) Inducible (CYP2C9) Inducible (CYP2C9) Some exhibit polymorphism Some exhibit polymorphism Rarely, some contribute to cancer formation

Phase 1: Rarely, some contribute to cancer formation Rarely, some contribute to cancer formation  An isoform of cytochrome P450 metabolize inactive PAHs (polycyclic aromatic hydrocarbons) into active carcinogens  PAHs are abundant in cigarette smoke  Smokers have increased levels of CYP1A1 in their cells than non-smokers.  CYP2E1 is induced by ethanol. CYP1A1, CYP2E1:

Phase 1: Microsomal cytochrome P450s Large number of isoforms Large number of isoforms All contains heme All contains heme Has a special nomenclature: Has a special nomenclature: Plenty in liver (in the SER) Plenty in liver (in the SER) Differs from the mitochondrial cytochrome P450 Differs from the mitochondrial cytochrome P450 Has lipid components (primarily lecithin) Has lipid components (primarily lecithin) Inducible (CYP2C9) Inducible (CYP2C9) Some exhibit polymorphism Rarely, some contribute to cancer formation

Phase 1: Some exhibit polymorphism Some exhibit polymorphism CYP2D6  CYP2D6 is involved in the metabolism of debrisoquin (antihypertensive drug) and sparteine (antiarrhythmic and oxytocic drug)  Polymorphisms (many different forms of CYP2D6 in the same medium) contribute to the lower the overall activity of the enzyme.  This is because some of the “variant forms” have low catalytic activity which pulls the overall activity down.  The poor catalysis of debrisoquin and sparteine allows them to stay and accumulate in the body and cause toxicity.  Polymorphisms and differences between enzyme structure between individuals is genetic

Phase 2 Conjugation reactions Enzyme: Transferases Purpose: Make the toxin further water- soluble for excretion

Processing of Xenobiotics Xenobiotic Reactive Metabolite Nontoxic Metabolite Cell injury Hapten Mutation Antibody reaction Cancer Out

Phase 2: Conjugation Rxn EnzymeDonor Examples of Xenobiotic Targets Glucoronidation (most frequently used by the body) Glucoronosyl-transferases UDP- glucoronic acid 2-acetylaminoflourene, benzoic acid, aniline, phenols Sulfation--- PAPS (active sulfate) Alcohols, arylamines, phenols Conj. w/ Glutathione --- G-SH form Electrophilic xenobiotics (R) R + G-SH  R-S-G R + G-SH  R-S-G Methylation Methyl- transferases SAM AcetylationAcetyl-CoAisoniazid